



**Watson Health**

## Recently Published Boehringer-Ingelheim Research with IBM MarketScan Claims Data

Click on title to view citation.

*[Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.](#)*

Gilligan AM, Franchino-Elder J, Song X, Wang C, Henriques C, Sainski-Nguyen A, Wilson K, Smith DM, Sander S. Expert Rev Pharmacoecon Outcomes Res 2019; 19(2): 203–212.

Healthcare researchers have used IBM® MarketScan® Research Databases to understand disease progression, treatment patterns, health outcomes, and their associated costs to patients, employers, health plans, and the government. Fully HIPAA compliant, the MarketScan Databases are among the largest proprietary databases used for healthcare research in the United States.

They are the basis of over 2,300 peer-reviewed articles published in leading journals since the first article appeared in The New England Journal of Medicine in 1990 (J.B. Hillman et al.). MarketScan-based research has made a substantial contribution to the body of literature used to formulate policy decisions and improve healthcare for Americans.

